News
![2 gene-editing stocks reshaping hereditary disease treatments: https://www.marketbeat.com/logos/articles/med_20231231121858_chart-ntla.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNkgrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d8cf7f26c4d9caf0889b2db456211e7f76836263/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231231121858_chart-ntla.jpg?locale=us)
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a
![Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals: https://www.marketbeat.com/logos/articles/med_20231228125224_bristol-myers-squibbs-big-buys-18.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBemo5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--172ff16f6c03f3a72068c04d412205991221957b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231228125224_bristol-myers-squibbs-big-buys-18.jpg?locale=us)
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
Bristol Myers Squibb Company (NYSE: BMY) is on a buying spree, announcing two acquisitions in less than a week.
On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc.
![Eilt: Biotech Hot Stock heilt Hautkrebs vollständig - Massives Kaufsignal. Diese Biotech-Aktie jetzt kaufen nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/73132/AC01-29-23_AC1.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0g4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d8ff5dcb07839f213b23490f0422598cb927fee3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC01-29-23_AC1.001.png?locale=us)
Eilt: Biotech Hot Stock heilt Hautkrebs vollständig - Massives Kaufsignal. Diese Biotech-Aktie jetzt kaufen nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Biotech Hot Stock heilt Hautkrebs vollständig - Kaufsignal. Diese Biotech-Aktie kaufen nach 15.973% mit BioNTech
29.12.23 08:03
London (www.aktiencheck.de, Anzeige)
![Neptune Digital Assets Corp. Announces the Release of Audited Financial Statements with a 56% Increase in Mining Revenues and 42% Increase in Digital Currency Balances over Prior Year: https://www.irw-press.at/prcom/images/messages/2023/73124/NDAAnnualFinancialResults_en_PRcom.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGY4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b39757ba33334362ea89c1cd477ae88da217453d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/NDAAnnualFinancialResults_en_PRcom.001.png?locale=us)
Neptune Digital Assets Corp. Announces the Release of Audited Financial Statements with a 56% Increase in Mining Revenues and 42% Increase in Digital Currency Balances over Prior Year
VANCOUVER, British Columbia – December 28, 2023 – Neptune Digital Assets Corp. (TSX-V:NDA) (OTCQB:NPPTF) (FSE:1NW) (“Neptune” or the "Company"), one of the first publicly traded blockchain
![Neptune Digital Assets Corp. veröffentlicht seinen geprüften Finanzbericht: 56 % Plus bei den Mining-Umsätzen und 42 % Plus beim digitalen Währungsguthaben gegenüber dem Vorjahr: https://www.irw-press.at/prcom/images/messages/2023/73124/NDAAnnualFinancialResults_de_PRcom.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGI4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--677baaf54c2c4c677a98702f560ff465fc157a28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/NDAAnnualFinancialResults_de_PRcom.001.png?locale=us)
Neptune Digital Assets Corp. veröffentlicht seinen geprüften Finanzbericht: 56 % Plus bei den Mining-Umsätzen und 42 % Plus beim digitalen Währungsguthaben gegenüber dem Vorjahr
VANCOUVER, British Columbia – 28. Dezember 2023 / IRW-Press / – Neptune Digital Assets Corp. (TSX-V: NDA) (OTCQB: NPPTF) (FWB: 1NW) („Neptune“ oder das „Unternehmen“), eines der ersten
![Eilt: Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs. Massives Kaufsignal. Diesen 359% Biotech Hot Stock jetzt kaufen nach 134.452% mit Biogen. Massives Kaufsignal. Jetzt 359% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.: https://www.irw-press.at/prcom/images/messages/2023/73122/AC12-28-23AC1.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGI4YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--708cb9a5928b8e9d3b2e446ddf1a0902dd017b6d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC12-28-23AC1.001.png?locale=us)
Eilt: Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs. Massives Kaufsignal. Diesen 359% Biotech Hot Stock jetzt kaufen nach 134.452% mit Biogen. Massives Kaufsignal. Jetzt 359% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.
Eilt: Biotech Hot Stock erzielt Durchbruch im Kampf gegen Hautkrebs. 359% Biotech Aktientip nach 134.452% mit Biogen
28.12.23 08:02
London (www.aktiencheck.de, Anzeige)
![Eilt: Hautkrebs vollständig geheilt - Massives Kaufsignal. Diesen 359% Biotech Hot Stock jetzt kaufen nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB): https://www.irw-press.at/prcom/images/messages/2023/73117/AC12-27-23_ac1.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNW43YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e77f9c81b3810f3c4c0a543b80ec5c39e0c501e3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC12-27-23_ac1.001.png?locale=us)
Eilt: Hautkrebs vollständig geheilt - Massives Kaufsignal. Diesen 359% Biotech Hot Stock jetzt kaufen nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB)
Eilt: Hautkrebs vollständig geheilt - Massives Kaufsignal. Neuer 359% Biotech Aktientip nach 15973% mit BioNTech ($BNTX)
27.12.23 08:02
London (www.aktiencheck.de, Anzeige)
![Align Technology: Protected by more factors than any other stock: https://www.marketbeat.com/logos/articles/med_20231226071503_align-technology-protected-by-more-factors-than-an.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMDM3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fa1ae640f2c06b2912e0858a5f4f13c96dc64e30/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231226071503_align-technology-protected-by-more-factors-than-an.jpg?locale=us)
Align Technology: Protected by more factors than any other stock
Because the past few months in the stock market have been a wild emotional roller coaster, most investors are now looking for the most logical and fundamental reasons to justify investing in any
![Pfizer's chaotic year wraps up with plunging stock, grim guidance: https://www.marketbeat.com/logos/articles/med_20231220201736_pfizers-chaotic-year-wraps-up-with-plunging-stock.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHo0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0533ff99e156078909ac5608d416e998eb2de42f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231220201736_pfizers-chaotic-year-wraps-up-with-plunging-stock.jpg?locale=us)
Pfizer's chaotic year wraps up with plunging stock, grim guidance
Investors who own Pfizer Inc. (NYSE: PFE) may have expected 2023 to be what football teams call a "rebuilding year." The company shifted its focus away from COVID-19 drugs and toward potential
![Eilt: Hautkrebs vollständig geheilt - Klinische Studie startet - Massives Kaufsignal. Diese Biotech-Aktie jetzt kaufen nach 134.452% mit Biogen. Massives Kaufsignal. Jetzt 381% mit Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfize: https://www.irw-press.at/prcom/images/messages/2023/73092/AC-211223.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNHI0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dbd361f3059abe70b8a6cf693c769c9405afc971/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/AC-211223.001.png?locale=us)
Eilt: Hautkrebs vollständig geheilt - Klinische Studie startet - Massives Kaufsignal. Diese Biotech-Aktie jetzt kaufen nach 134.452% mit Biogen. Massives Kaufsignal. Jetzt 381% mit Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfize
Eilt: Hautkrebs vollständig geheilt - Klinische Studie startet. Neuer 381% Biotech Aktientip nach 15.973% mit BioNTech
21.12.23 08:03
London (www.aktiencheck.de , Anzeige)
![5 Biotech stocks tapping into unmet mental health treatment needs: https://www.marketbeat.com/logos/articles/med_20231220075859_biotech-stocks-tapping-into-unmet-mental-health-tr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd3I0YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fe722b068bf814e31c65cbc6d3bdbbd1c5f5a8f3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231220075859_biotech-stocks-tapping-into-unmet-mental-health-tr.jpg?locale=us)
5 Biotech stocks tapping into unmet mental health treatment needs
Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are
![Eilt: Hautkrebs vollständig geheilt - Jetzt startet klinische Studie 2b. 525% Biotech Hot Stock nach 134.452% mit Biogen. Massives Kaufsignal. Jetzt 525% mit Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit A: https://www.irw-press.at/prcom/images/messages/2023/73082/Biotech_Aktiencheck01_201223.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFAzYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f2764696788f3ee876cba0ed84b64d1b01dc69e4/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Biotech_Aktiencheck01_201223.001.png?locale=us)
Eilt: Hautkrebs vollständig geheilt - Jetzt startet klinische Studie 2b. 525% Biotech Hot Stock nach 134.452% mit Biogen. Massives Kaufsignal. Jetzt 525% mit Biotech Hot Stock nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit A
Eilt: Hautkrebs vollständig geheilt - Jetzt startet klinische Studie 2b. 525% Biotech Hot Stock nach 134.452% mit Biogen
20.12.23
London (www.aktiencheck.de, Anzeige)
![Eilt: Biotech Aktientip startet Phase 2b-Studie zur Behandlung von Hautkrebs. Jetzt 525% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 525% mit Biote: https://www.irw-press.at/prcom/images/messages/2023/73055/Aktiencheck191223.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG4yYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--0382e9304419818262958cf390be4ff6af2a173a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Aktiencheck191223.001.png?locale=us)
Eilt: Biotech Aktientip startet Phase 2b-Studie zur Behandlung von Hautkrebs. Jetzt 525% mit Biotech Aktientip nach 3.296% mit BioNTech ($BNTX), 10.996% mit Pfizer ($PFE), 31.205% mit Amgen ($AMG) und 134.452% mit Biogen ($BIIB). Jetzt 525% mit Biote
Biotech Aktientip startet Phase 2b-Hautkrebs-Studie. Jetzt 525% mit Biotech Hot Stock nach 15.973% mit BioNTech ($BTNX)
19.12.23
London (www.aktiencheck.de, Anzeige)
Link
![Quick list of bargain stocks to end the year: https://www.marketbeat.com/logos/articles/med_20231215043651_quick-list-of-bargain-stocks-to-end-the-year.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNC96YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff92670faaed45f2492ef9db3a102f27e43b4194/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231215043651_quick-list-of-bargain-stocks-to-end-the-year.jpg?locale=us)
Quick list of bargain stocks to end the year
Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward
![AbbVie continues shopping spree with biotech buyout: https://www.marketbeat.com/logos/articles/med_20231212074517_abbvie-continues-shopping-spree-with-biotech-buyou.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmp2YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6eafcfb8da2fb15843e211c46e91e1b47be47190/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231212074517_abbvie-continues-shopping-spree-with-biotech-buyou.jpg?locale=us)
AbbVie continues shopping spree with biotech buyout
Christmas came early for Cerevel Therapeutics shareholders courtesy of AbbVie Inc. (NYSE:ABBV).
Last week, AbbVie announced a plan to acquire the Massachusetts-based biotechnology company in an
![3 biotech powerhouses poised to thrive amidst sector rebound: https://www.marketbeat.com/logos/articles/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMG5zYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--67afff63310fa8abbe501b0adbe50281d9e896b6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231208085353_3-biotech-powerhouses-poised-to-thrive-amidst-sect.jpg?locale=us)
3 biotech powerhouses poised to thrive amidst sector rebound
The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant
![Simply Good Foods: Winner in the Ozempic Weight-Loss Trend: https://www.marketbeat.com/logos/articles/med_20231203163352_chart-smpl2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMzNwYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2762bf404e64a2fbf04f8c14dadec64f0cab0f28/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231203163352_chart-smpl2.jpg?locale=us)
Simply Good Foods: Winner in the Ozempic Weight-Loss Trend
Nutritional food and snacks producer The Simply Good Foods Co. (NASDAQ: SMPL) has seen its shares rocket higher on the weight-loss medication trend led by Ozempic, Novo Nordisk A/S (NYSE: NVO)
![Ozempic vs. Mounjaro:: Battle of the bulge: https://www.marketbeat.com/logos/articles/med_20231204090609_battle-of-the-bulge-ozempic-vs.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeWZuYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a39a099341ade1b6b421b1b2b1e8cacee042fec7/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231204090609_battle-of-the-bulge-ozempic-vs.jpg?locale=us)
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused
![Mega merger in the works? Humana, Cigna explore big deal: https://www.marketbeat.com/logos/articles/med_20231201154241_mega-merger-in-the-works-humana-cigna-explore-big.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOHZsYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f0e54b22f4366b59a8485b6e113a963b5b9f062a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231201154241_mega-merger-in-the-works-humana-cigna-explore-big.jpg?locale=us)
Mega merger in the works? Humana, Cigna explore big deal
Consolidation in the health insurance industry has become a theme of 2023. Humana Inc. (NYSE: HUM) is reportedly in talks to merge with The Cigna Group (NYSE: CI) in a stock-and-cash deal
![J&J, Gilead, BMS: A look at undervalued dividend payers: https://www.marketbeat.com/logos/articles/med_20231128191819_jj-gilead-bms-a-look-at-undervalued-dividend-payer.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL2ZoYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9e758a18ead9bfe0dc993521a744e138a7625d8d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231128191819_jj-gilead-bms-a-look-at-undervalued-dividend-payer.jpg?locale=us)
J&J, Gilead, BMS: A look at undervalued dividend payers
Johnson & Johnson (NYSE: JNJ), Gilead Sciences Inc. (NYSE: GILD) and Bristol Myers Squibb Co. (NYSE: BMY) are among healthcare sector dividend-payers trading at low valuations relative to their
![BellRing Brands gets pumped on the Ozempic weight-loss trend: https://www.marketbeat.com/logos/articles/med_20231126113844_chart-brbr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0xmYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d6a8c22f1584e9975545442ba854fc45545ae133/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231126113844_chart-brbr.jpg?locale=us)
BellRing Brands gets pumped on the Ozempic weight-loss trend
Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss medication usage. While the name of
![Medtronic: oversold, overextended high yield reversal in play: https://www.marketbeat.com/logos/articles/med_20231121185742_medtronic-oversold-overextended-high-yield-reversa.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBekRkYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--6fcd99f44ac695af8838b8ab678ab87a88a6dbcc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231121185742_medtronic-oversold-overextended-high-yield-reversa.jpg?locale=us)
Medtronic: oversold, overextended high yield reversal in play
After two years of correction and downtrend, providing ample incentive to buyers all along the way, medical device maker Medtronic (NYSE: MDT) has finally reached its bottom, and the reversal is
![Safeguard your portfolio with these three bargain stocks: https://www.marketbeat.com/logos/articles/med_20231120184155_safeguard-your-portfolio-with-these-three-bargain.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd1BjYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--16d72789de22ff6a78648a3716df9e6b46586c86/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231120184155_safeguard-your-portfolio-with-these-three-bargain.jpg?locale=us)
Safeguard your portfolio with these three bargain stocks
Welcome to the jungle. Today's stock market is not the one you inherited from your parents or even your grandparents. In prior generations, information took a bit longer to spread across sectors
![Advanced Auto Parts may be worth more in pieces than the whole: https://www.marketbeat.com/logos/articles/med_20231119154016_chart-aap.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd2ZjYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--bfaad74cb551a29bce8a86e55f2c9266fc7487fb/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231119154016_chart-aap.jpg?locale=us)
Advanced Auto Parts may be worth more in pieces than the whole
Aftermarket auto parts retailer Advanced Auto Parts Inc. (NYSE: AAP) has dramatically underperformed its Auto/Tires/Trucks sector peers. Its shares are trading down 66.8% year-to-date (YTD)
![3 stocks that crushed earnings estimates and still tanked: https://www.marketbeat.com/logos/articles/med_20231119155357_chart-sghc.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK0RhYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--4dbeebcd5c630c02d18097c4b1268dcc6ab24309/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231119155357_chart-sghc.jpg?locale=us)
3 stocks that crushed earnings estimates and still tanked
Stocks that crush their earnings estimates are supposed to go up. However, that's not always the case. Every earnings season, regardless of sector or industry, has its share of stocks that report